Title Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo
Authors Ruan, Guo-Rui
Zhao, Hong-Shan
Chang, Yan
Li, Jin-Lan
Qin, Ya-Zhen
Liu, Yan-Rong
Chen, Shan-Shan
Huang, Xiao-Jun
Affiliation Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China.
Inst Hematol, Beijing 100044, Peoples R China.
Peking Univ, Ctr Human Dis Genom, Beijing 100083, Peoples R China.
Peking Univ, Peoples Hosp, 11 Xizhimen S St, Beijing 100044, Peoples R China.
Keywords PDCD5
gene therapy
adenoviral vector
idarubicin
leukemia
nude mice
TOPOISOMERASE-II
EXPRESSION PROFILES
BREAST-CANCER
TUMOR-CELLS
THERAPY
LEUKEMIA
MODEL
INHIBITORS
GROWTH
TFAR19
Issue Date 2008
Publisher apoptosis
Citation APOPTOSIS.2008,13,(5),641-648.
Abstract PDCD5 (programmed cell death 5) accelerates apoptosis of certain tumor cells and is expressed at low levels in marrow-nucleated cells of AML and CML patients. In the present study, we evaluated the effects of PDCD5 overexpression on drug sensitivity of leukemia cells. K562 cells were treated with idarubicin (IDR) alone or in combination with adenoviral vectors expressing PDCD5 (Ad-PDCD5). As shown by annexin-V-FITC/PI dual labeling, apoptosis rates were markedly increased after combined treatment with Ad-PDCD5 compared to IDR treatment alone. We observed that PDCD5 overexpression significantly improves the antitumor effects of low dose IDR treatment in vivo. Tumor sizes were significantly decreased in combined Ad-PDCD5 and low dose IDR treatment groups compared with single IDR treatment groups. Similar results were obtained with combined systemic treatment of Ad-PDCD5 and low dose IDR, and combined treatment with Ad-PDCD5 local injection and low dose IDR i.p. injection. These results indicate that Ad-PDCD5 may be a promising agent for enhancing chemosensitivity.
URI http://hdl.handle.net/20.500.11897/199179
ISSN 1360-8185
DOI 10.1007/s10495-008-0206-9
Indexed SCI(E)
PubMed
Appears in Collections: 人民医院

Web of Science®


31

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.